Toggle SGML Header (+)


Section 1: 8-K (FORM 8-K)

Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 14, 2016

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction

of incorporation)

 

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 14, 2016, the Board of Directors of Amedisys, Inc. (the “Company”) appointed Gary Willis as the Company’s Chief Financial Officer, effective as of January 3, 2017. Mr. Willis, 51, previously served as the Executive Vice President and Chief Financial Officer of Capella Healthcare, a healthcare services company, from September 2015 through the date of its merger with RegionalCare Hospital Partners in May 2016. Prior to Capella, Mr. Willis served as the Chief Financial Officer of Martin Ventures, a healthcare venture capital firm, from March 2014 through September 2015. Prior to Martin Ventures, Mr. Willis served as the Senior Vice President and Chief Accounting Officer of Vanguard Health Systems, a healthcare services company, from 2008 through March 2014.

Mr. Willis will participate in the Amedisys Holding, L.L.C. Severance Plan for Key Executives dated April 30, 2015, as amended. Mr. Willis does not have a family relationship with any of the current officers or directors of the Company. There is no currently proposed transaction, and since the beginning of fiscal year 2015 there has not been any transaction, involving the Company and Mr. Willis which was a related person transaction within the meaning of Item 404(a) of Regulation S-K.

Ronald A. LaBorde, the Vice Chairman and Chief Financial Officer of the Company, will continue to serve as the Company’s Chief Financial Officer through January 2, 2017 and will serve as Vice Chairman until April 2, 2017.

On December 16, 2016, the Company and Daniel P. McCoy, the Company’s Chief Operating Officer, mutually agreed that Mr. McCoy will be leaving the Company effective as of January 3, 2017 in connection with the previously announced appointment of Christopher Gerard as the Company’s Chief Operating Officer. Mr. McCoy’s departure from the Company will constitute a resignation with good reason.

 

Item 7.01. Regulation FD Disclosure.

On December 20, 2016, the Company issued a press release announcing the appointment of Mr. Willis as the Company’s Chief Financial Officer, effective January 3, 2017, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated December 20, 2016


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:  

/s/ Paul B. Kusserow

Paul B. Kusserow
President and Chief Executive Officer
DATE: December 20, 2016


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press Release dated December 20, 2016
(Back To Top)

Section 2: EX-99.1 (EX-99.1)

EX-99.1

Exhibit 99.1

 

LOGO   

Contact:

 

Kendra Kimmons

Managing Director of Communications

225-299-3708

kendra.kimmons@amedisys.com

Amedisys Welcomes Gary D. Willis as New Chief Financial Officer

BATON ROUGE, La., December 20, 2016 – Amedisys, Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, announced today that respected financial leader Gary D. Willis will join the Company as Chief Financial Officer effective January 3, 2017, and Ronald A. LaBorde will continue in his role as Vice Chairman until his retirement on April 2, 2017.

Willis is a senior financial executive with more than 25 years of experience, including 14 years in the healthcare industry. In his role as Chief Financial Officer, Willis will further drive stakeholder value by overseeing Amedisys’ financial operations, capital and financing strategies, accounting, public reporting (SEC) and investor relations for the Company.

“Gary’s financial expertise and experience in healthcare makes him an excellent addition to our executive team,” said President and CEO Paul Kusserow. “I would also like to acknowledge the many contributions Ronnie has made here at Amedisys. I’m appreciative that he is staying on through April 2 to ensure a seamless transition before his well-earned retirement.”

“I am excited to join Amedisys given the opportunity we have of becoming the industry leader in providing the highest quality of healthcare in the home,” stated Gary Willis. “Ronnie, SVP of Finance and Accounting Scott Ginn and their teams have done an excellent job in positioning the company for the future and I look forward to working with this talented group of people to continue the future success of Amedisys.”

Most recently, Willis served as Executive Vice President and Chief Financial Officer for Capella Healthcare Inc., based in Franklin, Tennessee. In addition to overseeing all financial operations of its acute care hospital facilities, Willis also guided the transition of the company from private equity ownership to an innovative capital structure with a public real estate investment trust.

Prior to Capella Healthcare, Willis served as Chief Financial Officer for Martin Ventures. He oversaw the financial aspects of the investment firm which focuses on equity and debt investments in young, high growth businesses, primarily in healthcare and technology.

Willis has also served as Senior Vice President and Chief Accounting Officer for Vanguard Health Systems, Inc., a Fortune 500 public healthcare company with revenues of $6 billion operating hospitals, health plans and related businesses; and Senior Vice President and Chief Accounting Officer for LifePoint, Health, Inc., a publicly-held healthcare services company.


A Certified Public Accountant, Gary earned his bachelor’s degree in accounting from Western Kentucky University.

#     #     #

About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

(Back To Top)